Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Future revenue from DRI Future Revenue Future Revenue Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Accrued expenses and other current liabilities Accrued Liabilities, Current Percentage of employee vested contribution Defined Contribution Plan, Employees Contribution, Vested Percentage Percentage vested of employee's contributions to defined contribution plan Range Statistical Measurement [Domain] Inventory valuation reserves Inventory Valuation Reserves Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Options granted, maximum term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period DRI Healthcare Acquisitions LP (DRI) DRI Healthcare Acquisitions LP (DRI) [Member] DRI Healthcare Acquisitions LP (DRI) Interest Income, Other Interest Income, Other Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Outstanding nonvested (in shares) Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Statement of Stockholders' Equity [Abstract] Research and Development Expenses, Including Clinical Trial Accruals/Expenses Research and Development Expense, Policy [Policy Text Block] Investments, Debt and Equity Securities [Abstract] Defined contribution plan, employer discretionary contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Lease liabilities Increase (decrease) in lease liabilities Increase (decrease) in lease liabilities MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Weighted-average remaining contractual term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Computer equipment Computer Equipment [Member] Net proceeds from sale of future royalties Net proceeds from sale of future royalties Net proceeds from sale of future royalties Restatement Determination Date: Restatement Determination Date [Axis] Operating lease liabilities Deferred Tax Assets, Operating Lease Liabilities Deferred Tax Assets, Operating Lease Liabilities NIAID National Institute of Allergy and Infectious Diseases [Member] Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies. Corporate debt securities Corporate debt securities Corporate Debt Securities [Member] Insider Trading Policies and Procedures [Line Items] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Construction in progress Construction in Progress, Gross Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Deferred revenue Deferred Revenue, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Aggregate intrinsic value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Employee service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Estimated Useful Lives Property Plant And Equipment Estimated Useful Life Table [Table Text Block] Property plant and equipment estimated useful life. Income Taxes Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Concentration Risk [Line Items] Concentration Risk [Line Items] Leases Lessee, Leases [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC [Member] McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Undesignated preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Basic and diluted net loss per common share, diluted (in dollars per share) Earnings Per Share, Diluted Unrealized Gain (Loss) on Investments Unrealized Gain (Loss) on Investments PEO Total Compensation Amount PEO Total Compensation Amount Liability related to future royalties Liability related to future royalties Liability related to future royalties Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Collaborative arrangement, term Collaborative Arrangement, Term Collaborative Arrangement, Term Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Revenue Collaboration And License Agreements Disclosure [Text Block] The entire disclosure for collaboration and license agreements. Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares) Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number RevenueFromRoyalityAgreementsMember RevenueFromRoyalityAgreementsMember [Member] RevenueFromRoyalityAgreementsMember Trading Symbol Trading Symbol RevenuesFromCMOAgreementsMember RevenuesFromCMOAgreementsMember [Member] RevenuesFromCMOAgreementsMember Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average grant-date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss Net loss Net Income (Loss) Net Income (Loss) Total current liabilities Liabilities, Current Right of use asset and lease liability increase Right of Use asset and Lease Liability Increase Right of Use asset and Lease Liability Increase Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Collaborative arrangement, extension term Collaborative Arrangement, Extension Term Collaborative Arrangement, Extension Term Company Selected Measure Name Company Selected Measure Name Non-refundable upfront payment Non-refundable upfront payment Initial fee received from collaboration or license agreement. Balance (in shares) Balance (in shares) Shares, Issued Liabilities and stockholders' equity Liabilities and Equity [Abstract] Employee Stock Employee Stock [Member] Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Deferred revenue Contract with Customer, Liability Cost of product sales Cost of Goods and Services Sold Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Proceeds from stock option exercises and ESPP purchases Proceeds from Stock Options Exercised And ESPP Purchases Proceeds from Stock Options Exercised And ESPP Purchases Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price upfront and fixed payments upfront and fixed payments upfront and fixed payments Quoted Prices in Active Markets for Identical Assets, Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Net deferred income tax assets Deferred Tax Assets, Net of Valuation Allowance Name Forgone Recovery, Individual Name Common stock maximum amount available for issuance Common Stock, Maximum Amount Available For Issuance Common Stock, Maximum Amount Available For Issuance Deferred income tax adjustments Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments. Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Indefinite Indefinite [Member] Indefinite Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Provention Bio CMO Agreeemnt Provention Bio CMO Agreeemnt [Member] Provention Bio CMO Agreeemnt Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Accounts receivable Accounts Receivable [Member] Number of product candidates to develop Number Of Product Candidates Number Of Product Candidates Measurement Frequency [Axis] Measurement Frequency [Axis] Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Federal U.S. net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards, Domestic Potential development and regulatory milestone payments Potential Development and Regulatory Milestone Payments Under Agreement Potential Development and Regulatory Milestone Payments Under Agreement Increases/(decreases) for prior year tax positions Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing Restricted Stock Units Restricted Stock Units (RSUs) [Member] Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount At The Market Offering At The Market Offering [Member] At The Market Offering [Member] 2022 Gilead Collaboration And License Agreement 2022 Gilead Collaboration And License Agreement [Member] 2022 Gilead Collaboration And License Agreement Depreciation expense Depreciation Equity-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Retirement Benefits [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Liability related to the sale of future royalties and related interest expense Liability related to future royalties and related interest expense [Policy Text Block] Liability related to future royalties and related interest expense Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Offering period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Cash, Cash Equivalents and Marketable Securities Cash and Cash Equivalents, Policy [Policy Text Block] Sale of common stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Cost of Product Sales and Cost of Manufacturing Services Cost of Goods and Service [Policy Text Block] Revenues Revenues Prepaid expenditures Deferred Tax Liabilities, Prepaid Expenses Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Lease, Cost Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Revenue from collaborative agreements Revenue From Collaborative Agreements [Member] Revenue From Collaborative Agreements Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Axis] Award Type [Axis] Potential milestone payment to third parties for intellectual property under agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement Anti-dilutive stock options Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Granted (in shares) Awards granted in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Liability Related to Future Royalty Liability Related to Future Royalty [Table Text Block] Liability Related to Future Royalty Non-cash operating and investing activities Noncash Investing and Financing Items [Abstract] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Interest expense Interest Expense Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Capital Expenditures Incurred but Not yet Paid Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cost of manufacturing services Cost of manufacturing services Cost of manufacturing services ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative General and Administrative Expense [Member] Share-based compensation, number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Property, equipment and software Property, Plant and Equipment, Gross Weighted-average remaining contractual term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating lease ROU assets Deferred Tax Liabilities, Operating Lease Right Of Use Assets Deferred Tax Liabilities, Operating Lease Right Of Use Assets Tax Year 2025 To 2037 Tax Year 2025 To 2037 [Member] Tax Year 2025 To 2037 Incyte MGA012 Clinical Services Incyte Commercial Supply Agreement [Member] Incyte Commercial Supply Agreement Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Transaction cost Transaction Cost Transaction Cost Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Lease liabilities Operating Lease, Liability, Current Prepaid expenses and other current assets Prepaid Expense, Current ASD Healthcare and Oncology Supply ASD Healthcare and Oncology Supply [Member] ASD Healthcare and Oncology Supply Auditor Information [Abstract] Auditor Information Amounts recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Available-for-sale, Allowance for Credit Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Deferred revenue, net of current portion Deferred Revenue, Noncurrent Auditor Firm ID Auditor Firm ID Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Incyte MGA012 Supply Agreement Incyte Clinical Supply Agreement [Member] Incyte Clinical Supply Agreement Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Synaffix B.V. Synaffix B.V. [Member] Synaffix B.V. Deferred transaction costs Deferred transaction costs Deferred transaction costs Increases for current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] 2016 Employee Stock Purchase Plan Two Thousand Sixteen Employee Stock Purchase Plan [Member] Two Thousand Sixteen Employee Stock Purchase Plan [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Undesignated Preferred Stock Undesignated Preferred Stock [Member] Undesignated Preferred Stock [Member] Government-sponsored enterprises Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] Sale of common stock (in dollars per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Deferred revenue, current Contract with Customer, Liability, Current Schedule of Employee Stock Options Award Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Research credit, net Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Total assets measured at fair value Assets, Fair Value Disclosure Proceeds of stock sale Sale of Stock, Consideration Received on Transaction Incyte Corporation (Incyte) Incyte Corporation [Member] Incyte Corporation [Member] Employee Stock Option Employee Stock Option [Member] Non-cash lease expense Operating Lease, Noncash Expense Operating Lease, Noncash Expense Balance at Beginning of Year Balance at End of Year SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Unrecognized compensation expense recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total costs and expenses Costs and Expenses Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrecognized compensation cost related to non-vested stock-based compensation arrangements Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount RevenuesFromGrantsMember RevenuesFromGrantsMember Document Type Document Type Tabular List, Table Tabular List [Table Text Block] U.S. Federal Government Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Gilead First Research Program Gilead First Research Program [Member] Gilead First Research Program Inventory Inventory, Policy [Policy Text Block] Eligible age to participate in plan Employees Eligible Age To Participate In Benefit Plan Refers to minimum eligible age of employee to participate in benefit plan. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock-based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Other non-cash items Other Noncash Income (Expense) Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Non-cash interest expense Non-cash interest expense recognized Non-cash interest expense recognized Total annual fixed payments Total Annual Fixed Payments Total Annual Fixed Payments Customer Concentration Risk Customer Concentration Risk [Member] Deferred revenue Deferred Tax Assets, Deferred Income Income Statement [Abstract] Issuance of common stock, net of offering costs (in shares) Number of shares issued or sold (in shares) Stock Issued During Period, Shares, New Issues Costs and expenses: Costs and Expenses [Abstract] Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure I-Mab Biopharma I-Mab Biopharma [Member] I-Mab Biopharma Sublease Income Sublease Income Zai Lab Limited (Zai Lab) Zai Lab Limited [Member] Zai Lab Limited Cardinal Health Cardinal Health, Inc [Member] Cardinal Health, Inc Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Gain on royalty monetization arrangement Gain on royalty monetization arrangement Gain on royalty monetization arrangement Gain on royalty monetization arrangement Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Additional annual fixed payments Additional Annual Fixed Payments Additional Annual Fixed Payments Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] United States federal tax at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Income Tax Examination [Line Items] Income Tax Examination [Line Items] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory, net Inventory, Net Lease, cost Lease, Cost Range [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Orphan drug credit, net Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount Principal payments on royalty monetization arrangement Principal payments on royalty monetization arrangement Principal payments on royalty monetization arrangement Total Shareholder Return Amount Total Shareholder Return Amount Product Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Inventory Disclosure [Abstract] Stock warrants (in shares) Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Transaction price Collaborative Agreement Transaction Price Collaborative Agreement Transaction Price Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Deferred income tax assets: Components of Deferred Tax Assets [Abstract] Components of the Company's Deferred Income Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Stock plan related activity Stock Issued During Period Value Stock Plan Activity Value of shares issued due to stock plan related activity. Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Operating lease payments Operating Lease, Payments Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Revenue from government agreements Revenue From Government Agreements [Member] Revenue From Government Agreements PEO PEO [Member] Consideration received common stock warrant exercise price (in usd per share) Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Employee Benefit Plan Retirement Benefits [Text Block] Asset Class [Domain] Asset Class [Domain] State taxes (net of federal benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Percentage of employee contribution to salary Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Sale of Stock [Axis] Sale of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Other permanent items Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Operating lease liabilities Operating Lease, Liability Total potential value Total potential value of agreement Refers to total potential value under agreement. 2021 Zai Lab Agreements 2021 Zai Lab Agreements [Member] 2021 Zai Lab Agreements Total liabilities Liabilities Provision for federal or state income taxes Current Income Tax Expense (Benefit) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Organization and Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Additions Charged to Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Measurement Frequency [Domain] Measurement Frequency [Domain] Property, Equipment and Software Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Deferred revenue, noncurrent Contract with Customer, Liability, Noncurrent Schedule Of Supplemental Balance Sheet Information, Operating Leases Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block] Schedule Of Supplemental Balance Sheet Information, Operating Leases Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Estimated Reimbursement for Research and Development t Estimated Reimbursement for Research and Development t Estimated Reimbursement for Research and Development t U.S. Federal and State Domestic Tax Authority and State and Local Jurisdiction [Member] [Member] Domestic Tax Authority and State and Local Jurisdiction [Member] [Member] SEC Schedule, 12-09, Reserve, Inventory SEC Schedule, 12-09, Reserve, Inventory [Member] Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,070,627 and 61,701,467 shares outstanding at December 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards, State and Local Total current assets Assets, Current Deferred state blended rate adjustments Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount Potential commercial milestone payments Potential Commercial Milestone Payments Under Agreement Potential Commercial Milestone Payments Under Agreement Summary of Percentage of Customer Concentration Schedules of Concentration of Risk, by Risk Factor [Table Text Block] All Individuals All Individuals [Member] Interest and other income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Reconciliation of Reported Estimated Income Tax Benefit Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Potential proceeds from royalties percent Proceeds from Royalties, Percent Proceeds from Royalties, Percent Beginning balance Ending balance Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Percentage of significant accounts receivable Concentration Risk, Percentage Undesignated preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Marketable securities Investments Investments Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Undesignated preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Accounts Receivable Accounts Receivable [Policy Text Block] Liability related to future royalty [Line Items] Liability related to future royalty [Line Items] Liability related to future royalty Depreciation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Orphan drug credit, net Deferred Tax Assets, Tax Credit Carryforwards, Other SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Proceeds from sales of equipment Proceeds from Sale of Machinery and Equipment Depreciation and amortization Depreciation, Depletion and Amortization Furniture Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Incyte MGA012 Agreement Incyte MGA012 Agreement [Member] Incyte MGA012 Agreement Statement of Financial Position [Abstract] Total stockholders' equity Balance Balance Equity, Attributable to Parent Gross unrecognized tax benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Valuation allowance Balance at Beginning of Year Balance at End of Year Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Deductions Valuation Allowance, Deferred Tax Asset, Decrease, Amount Valuation Allowance, Deferred Tax Asset, Decrease, Amount SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Royalty Monetization Arrangement Liability Related To Sale Of Future Royalties [Text Block] Liability Related To Sale Of Future Royalties Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Undesignated preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Laboratory and office equipment Laboratory and Office Equipment [Member] A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine. Significant Other Observable Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Finished goods Inventory, Finished Goods, Gross Gross deferred income tax assets Deferred Tax Assets, Gross Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Provention PRV3279 Provention PRV3279 [Member] Provention PRV3279 Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Weighted average exercise price (in dollars per share) Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Stock options and RSUs Stock Options And Restricted Stock Units [Member] Stock Options And Restricted Stock Units Common Stock Common Stock [Member] Royalty Monetization Arrangement [Abstract] Royalty Monetization Arrangement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Individual: Individual [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Royalty [Member] Royalty [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Summary of Fair Value Measurement Financial Assets Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Software Software and Software Development Costs [Member] Unrecognized interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Minimum Minimum [Member] Stock plan related activity (in shares) Stock Issued During Period Shares Stock Plan Activity Number of shares issued due to stock plan related activity. Property, equipment and software, net Property, equipment and software, net Property, Plant and Equipment, Net Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Other Deferred Tax Assets, Other Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Asset Purchase Agreement Asset Purchase Agreement [Member] Asset Acquisition Agreement U.S Treasury securities U.S. Treasury securities US Treasury Securities [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities James Karrels [Member] James Karrels Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Premium received on stock purchase Premium received on stock purchase Amount by which purchase price exceeds fair value for common stock purchased by collaborator. Accumulated Deficit Retained Earnings [Member] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders' equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other non current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Section 174 deferred tax asset Section 174 deferred tax asset Section 174 deferred tax asset Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Gilead Gilead [Member] Gilead Basic and diluted net loss per common share, basic (in dollars per share) Earnings Per Share, Basic Operating lease, ROU Assets Operating Lease, Right-of-Use Asset RevenuesFromCMOAmendmentAgreement RevenuesFromCMOAmendmentAgreement [Member] RevenuesFromCMOAmendmentAgreement Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Accumulated other comprehensive loss AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Net deferred income tax asset/(liability) Deferred Tax Assets, Net Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Weighted-average remaining contractual term, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized StockIncentivePlan2023Member StockIncentivePlan2023Member [Member] StockIncentivePlan2023Member Securities Fair Value Debt Securities, Available-for-Sale Additions Valuation Allowance, Deferred Tax Asset, Increase, Amount Valuation Allowance, Deferred Tax Asset, Increase, Amount Entity Public Float Entity Public Float Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Jeffrey Peters [Member] Jeffrey Peters Compensation Amount Outstanding Recovery Compensation Amount Proceeds from sale of future royalties Proceeds from sale of future royalties Proceeds from sale of future royalties Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash proceeds from exercise of stock options Proceeds from Stock Options Exercised Upfront payment from DRI Health Trust Upfront Payment Upfront Payment Loss on disposal of assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Forfeited or expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Work in process Inventory, Work in Process, Gross Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Aggregate intrinsic value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Common stock, shares issued (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Maximum employee contribution percent Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Other non current assets Increase (Decrease) in Other Operating Assets Adjustment to Compensation, Amount Adjustment to Compensation Amount Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Deferred income tax liabilities: Components of Deferred Tax Liabilities [Abstract] Auditor Name Auditor Name Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Royalty Monetization Arrangement [Table] Royalty Monetization Arrangement [Table] Royalty Monetization Arrangement Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense/(benefit) Income Tax Expense (Benefit) Income Tax Authority [Domain] Income Tax Authority [Domain] Number of operating segments Number of Operating Segments Sales revenue, net Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Issuance of common stock, net of offering costs Stock Issued During Period, Value, New Issues Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory, Net Inventory Disclosure [Text Block] Weighted average lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Discount rate Lessee, Operating Lease, Discount Rate Money market funds Money Market Funds [Member] Provention PRV031 Provention PRV031 [Member] Provention PRV031 US Federal tax credits carry forward Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Tax Period [Domain] Tax Period [Domain] Common stock purchased by employees (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Estimated useful lives Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Leasehold improvements Leasehold Improvements [Member] Diluted weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Furniture and office equipment Furniture And Office Equipment [Member] Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation. Summary of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Motor vehicles Vehicles [Member] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Lab equipment Equipment [Member] Zai Lab Zai Lab [Member] Zai Lab Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Tax Period [Axis] Tax Period [Axis] Fair Value, Recurring Fair Value, Recurring [Member] Other non current liabilities Other Liabilities, Noncurrent Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Revenues From License Agreements Revenues From License Agreements [Member] Revenues From License Agreements Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Other non current liabilities Increase (Decrease) in Deferred Rent The increase (decrease) during the reporting period in deferred rent. Provention License Agreement Provention License Agreement [Member] Provention License Agreement Number of performance obligations Number Of Performance Obligations Opt-in fee Opt-In Fee Opt-In Fee Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Clinical trial activities selling price amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Non-PEO NEO Non-PEO NEO [Member] Lease renewal term (in years) Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Percent of fair market value to purchase shares Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Research and development credit, net Deferred Tax Assets, Tax Credit Carryforwards, Research Text Block [Abstract] Text Block [Abstract] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic weighted average number of common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Inventory Reserves Schedule of Inventory Reserves [Table Text Block] Schedule of Inventory Reserves Loss from operations Operating Income (Loss) Valuation Allowance [Roll Forward] Valuation Allowance [Roll Forward] Valuation Allowance Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Revenues: Revenues [Abstract] Gross deferred income tax liabilities Deferred Tax Liabilities, Gross Provention Bio, Inc. (Provention) Provention Bio [Member] Provention Bio Collaboration and Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Stock Incentive Plan 2013 Stock Incentive Plan 2013 [Member] Stock Incentive Plan 2013 [Member] Concentration Risk [Table] Concentration Risk [Table] Property, Equipment and Software Property, Plant and Equipment, Policy [Policy Text Block] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] Target nomination, option fees and milestone Potential target nomination, option fees and milestone payments Potential target, nomination, option fees and milestone payments